Table II.

Clinical parameters of CI on ART subjects

Patient ID	CD4 (cells/µl)	CD8 (cells/µl)	Viral Loada	Treatment Regimen	Time Since Infection (mo)	Time of Aviremia (mo)
18	890	673	<50	AZT; 3TC; NEV	57	42
19	463	757	<50	3TC; EFV; ABA	152	20
20	602	767	<50	3TC; ABA; SAQ	158	53
21	563	613	<50	IND; 3TC; AZT	86	71
22	424	461	<50	3TC; D4T; DEL	84	46
23	731	413	<50	EFV; AZT; 3TC	51	22
24	834	527	<50	NEV; ATA; TENO; RIT	38	25
25	552	715	<50	D4T; ATA	139	56
26	671	1,120	<50	3TC; ABA; LOP; RIT	242	64
27	510	765	<50	AZT; 3TC; RIT	61	52
28	799	1,727	<50	3TC; D4T; NEV	62	33
42	501	278	<50	D4T; 3TC; IND	90	87
43	344	642	<50	3TC; D4T; NEV	59	44
44	604	1,281	<50	IND; AZT; 3TC	53	35
47	443	322	<50	RIT; AZT; 3TC; KAL	18	12
56	599	923	<50	AZT; 3TC; EFV	86	46
57	688	1,273	<50	AZT; 3TC; EFV	100	59
58	434	583	<50	3TC; EFV; ABA	165	34
59	492	582	<50	RIT; ABC; 3TC; ATA	170	66
60	529	690	<50	3TC; D4T; DEL	49	11
61	888	942	<50	NA	NA	NA
62	836	1236	267	NA	NA	NA
63	883	333	<50	EFV; IND	89	78
Median	599	690	–	–	86	46

^aHIV RNA copies per milliliter of plasma.

3TC, Lamivudine; ABA/ABC, Abacavir; ATA, Atazanavir; AZT, Zidovudine; D4T, Stavudine; DEL, Delavirdine; EFV, Efavirenz; IND, Indinavir; KAL, Kaletra; LOP, Lopinavir; NA, not available; NEV, Nevirapine; RIT, Ritonavir; SAQ, Saqui-navir; TENO, Tenofovir.